GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Cash Flow from Discontinued Operations

BCYC (Bicycle Therapeutics) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Bicycle Therapeutics's cash flow from discontinued operations for the three months ended in Sep. 2024 was $0.00 Mil. It means Bicycle Therapeutics received $0.00 Mil from the sale of part of business quarterly. Bicycle Therapeutics's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Bicycle Therapeutics Cash Flow from Discontinued Operations Historical Data

The historical data trend for Bicycle Therapeutics's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics Cash Flow from Discontinued Operations Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial - - - - -

Bicycle Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bicycle Therapeutics Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicycle Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Cash Flow from Discontinued Operations
Comparable Companies
ZYME BCAX AVXL VIR UPB LQDA SPRY PHVS REPL GYRE VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
50BA:Germany
Address
Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Website
https://www.bicycletherapeutics.com
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Executives
Travis Alvin Thompson officer: Chief Accounting Officer C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Nigel Crockett officer: Chief Business Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Alistair Milnes officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee director, officer: Chief Executive Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Michael Skynner officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Nicholas Keen officer: Chief Scientific Officer C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Lee Kalowski officer: President and CFO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Santiago Arroyo officer: Chief Development Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Dominic Smethurst officer: Chief Medical Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham director 1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098